After months of teleconferences, the DolPHIN-2 project team finally came face to face at our first consortium meeting.
At the end of March, we gathered in Cape Town, South Africa to kick off the project, which is looking at the HIV medication, dolutegravir, to see if it works better than existing medication used in Uganda and South Africa in late presenting pregnant women, with the aim of preventing mother to child transmission of HIV.
Representatives from all the collaborators (University of Liverpool, Liverpool School of Tropical Medicine, Radboud University, Infectious Disease Institute, Uganda, University of Cape Town) attended the meeting - even though the luggage containing reference material arrived a day or two late.
We had a very productive few days discussing all aspects of the project that include a clinical trial, health pharmacoeconomics and qualitative work looking at the acceptability of dolutegravir.
We also visited one of the trial sites and were given a grand tour of the facilities at Gugulethu Community Health Clinic. It was a pleasure to meet and chat with the clinic staff. The clinical trial is due to start recruitment in September 2017.
Now we are all full of enthusiasm to get DolPHIN-2 up and running. The meeting also allowed us to discover what talent we have on board which included singers and a gymnast! I will leave you to guess who had which talent.